Genprex, Inc., is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. The company’s lead product candidate, Oncoprex™, is being evaluated as a treatment for NSCLC.

Learn more about our lead drug candidate for non-small cell lung cancer and our non-viral nanoparticle delivery platform at